• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Cancer Diagnostics Market Size

    ID: MRFR/MED/1430-HCR
    200 Pages
    Rahul Gotadki
    October 2025

    Cancer Diagnostics Market Size, Growth Research Report By Test Type (Biopsy, Imaging, Blood Tests, Molecular Testing), By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer), By End User (Hospitals, Diagnostic Laboratories, Research Institutes), By Sample Type (Tissue Samples, Blood Samples, Urine Samples) and By Regional (North America, Europe, South America, Asia Paci...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Cancer Diagnostics Market Infographic

    Purchase Options

    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Summary Table of Contents Segmentation Download PDF

    Cancer Diagnostics Size

    Cancer Diagnostics Market Growth Projections and Opportunities

    The cancer diagnostics market is impacted by a huge number of elements that by and large lay out its geology and patterns in extension. The worldwide expansion in disease rate is a critical element driving business sector development. Subsequently, the rising interest for ahead of schedule and exact demonstrative apparatuses impels the development of the cancer diagnostics market. Market extension is pushed by mechanical advancements, for example, cutting edge sequencing, fluid biopsy, and atomic imaging, which improve the precision and speed of malignant growth finding. A maturing populace expands vulnerability to disease, subsequently increasing the interest for demonstrative arrangements. Subsequently, the interest in cancer demonstrative instruments and administrations has expanded. Market development is being pushed by an expansion in open mindfulness and administrative drives to energize preventive malignant growth screening programs. Customary disease screening works with lucky malignant growth location, which thusly improves patient results and treatment. The improved mindfulness among people in regard to the criticality of early disease discovery is a crucial component driving the market. Through outreach drives, for example, instructive missions, the market extends. For market development, public subsidizing for malignant growth research and analytic projects is fundamental. Help from the public authority and monetary help encourage a good climate for Research and development. A shift toward customized diagnostics and accuracy medication is changing the market climate. Custom-made analytic methods yield viable treatment procedures, along these lines invigorating business sector development. The execution of disease analytic methods is affected by monetary factors like instalment rules and medical care use. Monetary solidness and positive repayment guidelines increment the accessibility and utilization of analytic advances. The inclinations of patients for negligibly or only intrusive symptomatic methodology decide market patterns. Indicative instruments that focus on the solace of the patient are bound to be acknowledged. Severe quality affirmation and administrative prerequisites impact the market climate. Organizations that stick to administrative necessities and acquire endorsements quickly lay out validity and client trust. Various features of medical services have been impacted by the Coronavirus pandemic, including malignant growth location. The market has been affected by disturbances in clinical benefits and postpones in screening strategies; recuperation is dependent upon the general pandemic circumstance.

    Cancer Diagnostics Market Size Graph

    Market Summary

    As per Market Research Future Analysis, the Cancer Diagnostics Market was valued at 189.19 USD Billion in 2024 and is projected to reach 386.19 USD Billion by 2035, reflecting a CAGR of 6.70% from 2025 to 2035. The market is driven by the increasing incidence of cancer globally, advancements in diagnostic technologies, and growing awareness of early detection.

    Key Market Trends & Highlights

    Key trends driving the Cancer Diagnostics Market include technological advancements and increased awareness.

    • The global cancer diagnostics market is expected to grow from 16.41 USD Billion in 2024 to 24 USD Billion by 2035. Biopsy segment is projected to rise from 5.0 USD Billion in 2024 to 7.2 USD Billion by 2035. North America is expected to hold a majority market share valued at 8.0 USD Billion in 2024, growing to 11.5 USD Billion by 2035. Investment in R&D is increasing, with billions allocated annually to enhance diagnostic capabilities.

    Market Size & Forecast

    2024 Market Size USD 189.19 Billion
    2035 Market Size USD 386.19 Billion
    CAGR (2025-2035) 6.70%
    Largest Regional Market Share in 2024 North America.

    Major Players

    <p>Key players include Abbott Laboratories, Hologic, Myriad Genetics, Thermo Fisher Scientific, BioMérieux, Exact Sciences, Castle Biosciences, Roche, Seegene, Illumina, Agilent Technologies, F. Hoffmann-La Roche, Qiagen, Philips Healthcare, Siemens Healthineers.</p>

    Market Trends

    The Cancer Diagnostics Market is currently experiencing significant trends driven by advancements in technology and an increasing focus on early detection. Key market drivers include the rising incidence of cancer globally, which has led to heightened awareness and demand for diagnostic services. Governments and health organizations are prioritizing cancer screening programs, thereby increasing access to diagnostic tools. This rise is also supported by improvements in imaging technologies, biomarker discovery, and genetic testing, which enhance the precision of cancer diagnosis and monitoring.

    Opportunities to be explored in the Cancer Diagnostics Market involve the integration of artificial intelligence and machine learning into diagnostic procedures.These new technologies should make it easier and faster to find cancer, which will let doctors make treatment plans that are more tailored to each patient. Additionally, developing countries have the potential for growth because more money spent on healthcare infrastructure can make it easier for people to get advanced diagnostic tools, which will help the market grow. Recent trends show a move towards liquid biopsy techniques, which are less invasive ways to find cancer markers in blood samples.

    There is a huge need for these kinds of new solutions, especially in places where traditional diagnostic methods may not work as well. Also, the partnership between private companies and health authorities is getting stronger, which should make cancer tests even more available and affordable.

    Overall, the Cancer Diagnostics Market is rapidly evolving, driven by technological advancements and a concerted effort to improve patient outcomes through early and accurate diagnosis.

     

    Source: Primary Research, Secondary Research, Market Research Future Database, and Analyst Review

    <p>The ongoing advancements in molecular diagnostics and personalized medicine are reshaping the landscape of cancer detection, enhancing early diagnosis and treatment options for patients globally.</p>

    U.S. National Cancer Institute

    Cancer Diagnostics Market Market Drivers

    Market Growth Projections

    The Global Cancer Diagnostics Market Industry is poised for substantial growth, with projections indicating a market value of 16.4 USD Billion in 2024 and an anticipated increase to 24 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate of 3.52% from 2025 to 2035. Factors contributing to this growth include rising cancer incidence, technological advancements, and increased government funding for cancer research. The market dynamics are further influenced by growing awareness of cancer screening and the expansion of healthcare infrastructure in emerging markets. Overall, the market is expected to evolve significantly, driven by a combination of these interrelated factors.

    Rising Incidence of Cancer

    The Global Cancer Diagnostics Market Industry is experiencing growth due to the rising incidence of cancer worldwide. According to the World Health Organization, cancer cases are projected to increase significantly, with an estimated 19.3 million new cases diagnosed in 2020. This alarming trend necessitates advanced diagnostic tools to facilitate early detection and treatment. As a result, the market is expected to reach 16.4 USD Billion in 2024, reflecting a growing demand for innovative diagnostic solutions. The increasing prevalence of various cancer types, including lung, breast, and colorectal cancers, underscores the urgent need for effective diagnostic methods, driving investments in research and development.

    Government Initiatives and Funding

    Government initiatives and funding are crucial drivers of the Global Cancer Diagnostics Market Industry. Many countries are increasing their investments in cancer research and diagnostic technologies to combat the rising cancer burden. For example, the National Cancer Institute in the United States allocates substantial funding for cancer research, which includes the development of innovative diagnostic tools. Such initiatives not only promote advancements in technology but also encourage collaboration between public and private sectors. This support is expected to facilitate the growth of the market, contributing to a compound annual growth rate of 3.52% from 2025 to 2035. Enhanced funding mechanisms are likely to accelerate the development and adoption of novel diagnostic solutions.

    Emerging Markets and Demographic Changes

    Emerging markets and demographic changes are reshaping the Global Cancer Diagnostics Market Industry. As populations in developing regions grow and age, the demand for cancer diagnostics is expected to rise. Countries in Asia-Pacific and Latin America are witnessing an increase in cancer cases, driven by lifestyle changes and aging populations. This demographic shift presents significant opportunities for market expansion, as healthcare systems in these regions invest in improving diagnostic capabilities. The increasing focus on healthcare infrastructure development is likely to facilitate access to advanced diagnostic technologies, thereby enhancing early detection rates. The market's growth trajectory is expected to be positively influenced by these demographic trends.

    Growing Awareness and Screening Programs

    Growing awareness regarding cancer and the importance of early detection is significantly influencing the Global Cancer Diagnostics Market Industry. Public health campaigns and screening programs are increasingly encouraging individuals to undergo regular screenings, leading to earlier diagnosis and improved survival rates. For instance, initiatives promoting mammography for breast cancer and colonoscopy for colorectal cancer have been widely adopted. This heightened awareness is expected to drive market growth, as more individuals seek diagnostic services. As a result, the market is projected to expand, with a notable increase in demand for screening tests and diagnostic imaging services. The proactive approach to cancer detection is likely to enhance overall public health outcomes.

    Technological Advancements in Diagnostics

    Technological advancements play a pivotal role in shaping the Global Cancer Diagnostics Market Industry. Innovations such as liquid biopsy, next-generation sequencing, and artificial intelligence are revolutionizing cancer detection and diagnosis. These technologies enhance precision, reduce time to diagnosis, and improve patient outcomes. For instance, liquid biopsy allows for non-invasive testing, enabling the detection of cancer at earlier stages. As these technologies gain traction, they are expected to contribute significantly to market growth, with projections indicating a market value of 24 USD Billion by 2035. The integration of advanced technologies into diagnostic processes is likely to enhance the overall efficiency and effectiveness of cancer care.

    Market Segment Insights

    Cancer Diagnostics Market Test Type Insights

    <p>The Cancer Diagnostics Market is characterized by a diverse array of test types that play a critical role in the early detection and diagnosis of various cancer forms. In 2024, the overall market is projected to be valued at 16.41 USD billion, reflecting the increasing emphasis on advanced diagnostic techniques across the globe. The segment of Test Type is marked by several key areas: Biopsy, Imaging, Blood Tests, and Molecular Testing, each with its own significance and market contributions.</p>

    <p>The Biopsy segment is recognized as a major player with a valuation of 4.0 USD billion in 2024, projected to rise to 6.0 USD billion by 2035, underscoring its critical role in confirming cancer diagnoses through tissue examination.</p>

    <p>Imaging, as another crucial area, stands at 5.5 USD billion in 2024, anticipated to grow to 8.5 USD billion by 2035, highlighting the growing adoption of technologies like MRI, CT scans, and PET scans that aid in visualizing tumors and evaluating their extent. Blood Tests, valued at 3.0 USD billion in 2024, are forecasted to expand to 4.5 USD billion by 2035, as liquid biopsies emerge to capture circulating tumor cells and biomarkers, facilitating non-invasive monitoring of cancer.</p>

    Cancer Diagnostics Market Cancer Type Insights

    <p>The Cancer Diagnostics Market is experiencing significant growth, where the market is expected to reach a value of 16.41 billion USD by 2024. The market segmentation according to Cancer Type includes important categories such as Breast Cancer, Lung Cancer, Prostate Cancer, and Colorectal Cancer, which are crucial in the diagnostics landscape. Breast Cancer remains a prominent concern globally, significantly driving demand for advanced diagnostic tools due to its high prevalence and public awareness initiatives.</p>

    <p>Lung Cancer diagnostics also holds importance, as early detection greatly influences survival rates and treatment outcomes.Prostate Cancer is another segment that demands focused diagnostic strategies, with increasing incidence rates driving the need for effective screening methods. Colorectal Cancer diagnostics plays a vital role, especially given its rising occurrence, making effective detection essential for improving patient prognoses.</p>

    <p>This segmentation not only highlights key areas within the Cancer Diagnostics Market but also underlines the ongoing clinical advancements and technologies that are pivotal for accurate diagnoses and improved patient management strategies in the healthcare system.The well-defined segments reflect the market's efforts to address diverse diagnostic needs, ultimately enhancing treatment pathways and patient outcomes.</p>

    Cancer Diagnostics Market End User Insights

    <p>The Cancer Diagnostics Market is projected to be valued at 16.41 USD Billion in 2024, showcasing substantial relevance to the End User segment, which comprises hospitals, diagnostic laboratories, and research institutes. Hospitals represent a significant portion of the market, providing comprehensive cancer care and advanced diagnostic technologies to improve patient outcomes. Diagnostic laboratories play a crucial role in analyzing samples and ensuring timely and accurate results, which are vital for effective treatment planning.</p>

    <p>Research institutes contribute by driving innovation and advancements in cancer diagnostics, leading to the development of novel diagnostic tools and techniques.As the demand for early detection and personalized medicine grows, the market sees an increase in the utilization of advanced diagnostic methods across these End User segments. Cancer Diagnostics Market statistics suggest that the interplay between these segments is essential for enhancing diagnostic accuracy and enabling better patient management, underscoring their importance in the overall landscape of cancer care.</p>

    <p>The continuous advancements in technologies and an increasing focus on early detection present new opportunities for growth within the End User category.</p>

    Cancer Diagnostics Market Sample Type Insights

    <p>The Cancer Diagnostics Market, with a valuation projected at 16.41 USD billion in 2024, encompasses various Sample Type categories that play a pivotal role in cancer detection and management. One of the most significant components is Tissue Samples, which provide vital insights for pathologists, allowing for precise diagnosis and tailored treatment plans. Blood Samples have gained popularity due to their minimally invasive nature, enabling early detection and monitoring of cancer biomarkers.</p>

    <p>Furthermore, Urine Samples are emerging as valuable tools, providing a non-invasive option for detecting certain cancers.The increasing prevalence of cancer and the growing emphasis on early diagnosis are major growth drivers in this sector. The market's segmentation reflects these trends, with each sample type offering unique advantages that cater to various diagnostic needs. Moreover, advancements in technologies and a rising push for personalized medicine are likely to enhance the overall efficiency and accuracy of cancer diagnostics globally.</p>

    <p>Additionally, the increasing collaboration between healthcare providers and research institutions is crucial for developing innovative diagnostic solutions.Overall, the Cancer Diagnostics Market is evolving rapidly, presenting opportunities for enhancing patient outcomes.</p>

    Get more detailed insights about Cancer Diagnostics Market Research Report - Forecast till 2035

    Regional Insights

    The Regional segment of the Cancer Diagnostics Market shows notable diversity, with North America leading the market, valued at 6.5 USD Billion in 2024, projected to reach 9.5 USD billion by 2035, showcasing its majority holding due to advanced healthcare infrastructure and significant Research and Development investment. Europe follows, valued at 4.0 USD billion in 2024 and expected to grow to 5.5 USD billion by 2035, driven by increasing awareness and early detection initiatives.

    The Asia Pacific region is gaining momentum, with a valuation of 3.0 USD Billion in 2024 and rising to 5.0 USD billion by 2035, attributed to a growing population and rising healthcare expenditure.South America, valued at 1.5 USD Billion in 2024, will increase to 2.0 USD billion in 2035, highlighting potential growth opportunities amidst emerging market dynamics. Meanwhile, the Middle East and Africa, with a value of 1.41 USD billion in 2024 projected to reach 2.0 USD billion by 2035, illustrating the region's gradual improvement in healthcare access and cancer diagnostics.

    The continuous advancements in technology and improving regulatory frameworks across these regions further enhance market growth, while varied challenges persist in healthcare affordability and awareness, particularly in developing regions.

    Cancer Diagnostics Market Regional Insights

    Source: Primary Research, Secondary Research, Market Research Future Database, and Analyst Review

    Key Players and Competitive Insights

    The Cancer Diagnostics Market is characterized by intense competition driven by the growing prevalence of cancer and advancements in diagnostic technologies. In recent years, the market has seen a surge in the development of innovative diagnostic tools that enhance early detection and personalized treatment. With increasing awareness about cancer screening and burgeoning investment in research and development, key players in this field are continually striving to maintain their competitive edge. 

    Factors such as the rise in healthcare expenditure, the demand for precise diagnostic methods, and regulatory changes aimed at improving cancer care contribute to a dynamic market landscape. Companies are focusing on strategies such as collaborations, mergers, and acquisitions to expand their product portfolios and enhance their market presence, ultimately focusing on delivering effective solutions to meet the increasing healthcare demands of the global population.F. Hoffmann-La Roche, often referred to as Roche, occupies a major position in the Cancer Diagnostics Market, leveraging its strong portfolio of innovative products and solutions tailored for cancer detection and treatment.

    The company is known for its commitment to advancing personalized healthcare and integrating diagnostics with treatment processes. Roche’s robust pipeline of diagnostic assays, particularly its expertise in companion diagnostics, enhances its ability to provide targeted therapies. 

    The company’s strong brand reputation, extensive distribution channels, and continuous investment in research make it a formidable player within the market. Moreover, Roche's established collaborations with healthcare providers and research institutions underscore its focus on enhancing diagnostic accuracy and effectiveness, solidifying its position as a leader in the cancer diagnostics space.Thermo Fisher Scientific is recognized for its comprehensive approach to the Cancer Diagnostics Market, providing a wide range of products and services that cater to various aspects of cancer detection and monitoring. The company offers advanced diagnostic technologies, including next-generation sequencing, immunoassays, and molecular diagnostic tools.

    Its strong global presence is bolstered by strategic mergers and acquisitions that expand its capabilities and enhance its product portfolio. 

    By acquiring companies with innovative technologies, Thermo Fisher Scientific has strengthened its position in the oncology diagnostics sector. Additionally, the company emphasizes the development of integrated systems that facilitate research and clinical applications, enabling healthcare providers to adopt effective cancer management strategies. The commitment to quality, innovation, and customer support cements Thermo Fisher Scientific's reputation as a key player in the global cancer diagnostics landscape.

    Key Companies in the Cancer Diagnostics Market market include

    Industry Developments

    Recent developments in the Cancer Diagnostics Market have showcased significant advancements and growing investments, reflecting the increasing demand for early detection methods. Companies such as F. Hoffmann-La Roche and Illumina have been at the forefront, introducing innovative diagnostic solutions and technologies. In September 2023, Thermo Fisher Scientific announced a strategic collaboration with Agilent Technologies to enhance biomarker discovery, aimed at improving cancer diagnostics accuracy and efficiency. Moreover, the market has recently experienced a wave of mergers; in August 2023, LabCorp announced its acquisition of BioRad Laboratories' clinical diagnostics unit, bolstering its position in the oncology testing segment.

    The growing trend of personalized medicine has further accelerated the market, as pharmaceutical companies like Bristol-Myers Squibb focus on companion diagnostics that complement targeted therapies. Market valuation for leading companies is on the rise due to increased healthcare spending and a more substantial emphasis on precision medicine, creating a favorable environment for growth in the cancer diagnostics sector. Overall, the current landscape is characterized by innovation, collaboration, and significant investment aimed at improving cancer detection and patient outcomes globally.

    Future Outlook

    Cancer Diagnostics Market Future Outlook

    <p>The Global Cancer Diagnostics Market is projected to grow at a 6.70% CAGR from 2025 to 2035, driven by technological advancements, increasing cancer prevalence, and enhanced screening initiatives.</p>

    New opportunities lie in:

    • <p>Develop AI-driven diagnostic tools for early cancer detection. Expand telemedicine services for remote diagnostics and consultations. Invest in personalized medicine approaches to tailor diagnostics based on genetic profiles.</p>

    <p>By 2035, the market is expected to exhibit robust growth, reflecting advancements in diagnostic technologies and increased demand.</p>

    Market Segmentation

    Cancer Diagnostics Market End User Outlook

    • Hospitals
    • Diagnostic Laboratories
    • Research Institutes

    Cancer Diagnostics Market Regional Outlook

    • North America
    • Europe
    • South America
    • Asia Pacific
    • Middle East and Africa

    Cancer Diagnostics Market Test Type Outlook

    • Biopsy
    • Imaging
    • Blood Tests
    • Molecular Testing

    Cancer Diagnostics Market Cancer Type Outlook

    • Breast Cancer
    • Lung Cancer
    • Prostate Cancer
    • Colorectal Cancer

    Cancer Diagnostics Market Sample Type Outlook

    • Tissue Samples
    • Blood Samples
    • Urine Samples

    Report Scope

    Report Attribute/MetricDetails
    Market Size 2024189.19 (USD Billion)
    Market Size 2035386.19 (USD Billion)
    Compound Annual Growth Rate (CAGR)6.70% (2025 - 2035)
    Report CoverageRevenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year2024
    Market Forecast Period2025 - 2035
    Historical Data2019 - 2024
    Market Forecast UnitsUSD Billion
    Key Companies ProfiledF. Hoffmann-La Roche, Thermo Fisher Scientific, PerkinElmer, Agilent Technologies, Siemens Healthineers, Hologic, Laboratory Corporation of America Holdings, Genomic Health, Qiagen, Roche, BristolMyers Squibb, Illumina, Abbott Laboratories, BioRad Laboratories
    Segments CoveredTest Type, Cancer Type, End User, Sample Type, Regional
    Key Market OpportunitiesRise in early detection technologies, Increasing demand for liquid biopsy, Advancements in genomic profiling, Growing use of AI in diagnostics, Expanding telemedicine for remote testing
    Key Market DynamicsIncreasing prevalence of cancer, Advancements in diagnostic technologies, Rising demand for early detection, Growth of personalized medicine, Expanding biomarker research
    Countries CoveredNorth America, Europe, APAC, South America, MEA
    Market Size 2025201.87 (USD Billion)

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM
    View All

    FAQs

    What is the expected market size of the Cancer Diagnostics Market in 2024?

    The Cancer Diagnostics Market is expected to be valued at 16.41 billion USD in 2024.

    What is the projected market value of the Cancer Diagnostics Market by 2035?

    By 2035, the Cancer Diagnostics Market is projected to reach a value of 24.0 billion USD.

    What is the expected CAGR for the Cancer Diagnostics Market from 2025 to 2035?

    The expected CAGR for the Cancer Diagnostics Market from 2025 to 2035 is 3.52%.

    Which region is anticipated to dominate the Cancer Diagnostics Market in 2024?

    North America is anticipated to dominate the Cancer Diagnostics Market with a valuation of 6.5 billion USD in 2024.

    How much is the European market for Cancer Diagnostics projected to grow by 2035?

    The European market for Cancer Diagnostics is projected to grow to 5.5 billion USD by 2035.

    What is the expected market size for biopsies in the Cancer Diagnostics Market by 2035?

    The market size for biopsies in the Cancer Diagnostics Market is expected to reach 6.0 billion USD by 2035.

    Who are the major players in the Cancer Diagnostics Market?

    Major players in the Cancer Diagnostics Market include F. Hoffmann-La Roche, Thermo Fisher Scientific, and Siemens Healthineers.

    What will the market size for molecular testing be in 2035?

    The market size for molecular testing in the Cancer Diagnostics Market is expected to be 5.0 billion USD by 2035.

    What is the value of the Blood Tests segment in the Cancer Diagnostics Market for 2024?

    The Blood Tests segment in the Cancer Diagnostics Market is valued at 3.0 billion USD in 2024.

    Which region shows significant growth potential in the Cancer Diagnostics Market by 2035?

    Asia Pacific shows significant growth potential in the Cancer Diagnostics Market, expected to reach 5.0 billion USD by 2035.

    1. --- "
    2. Table of Contents
    3. EXECUTIVE SUMMARY
    4. Market Overview
    5. Key Findings
    6. Market Segmentation
    7. Competitive Landscape
    8. Challenges and Opportunities
    9. Future Outlook
    10. MARKET INTRODUCTION
    11. Definition
    12. Scope of the study
    13. Research Objective
    14. Assumption
    15. Limitations
    16. RESEARCH METHODOLOGY
    17. Overview
    18. Data Mining
    19. Secondary Research
    20. Primary Research
    21. Primary Interviews and Information Gathering Process
    22. Breakdown of Primary Respondents
    23. Forecasting Model
    24. Market Size Estimation
    25. Bottom-Up Approach
    26. Top-Down Approach
    27. Data Triangulation
    28. Validation
    29. MARKET DYNAMICS
    30. Overview
    31. Drivers
    32. Restraints
    33. Opportunities
    34. MARKET FACTOR ANALYSIS
    35. Value chain Analysis
    36. Porter's Five Forces Analysis
    37. Bargaining Power of Suppliers
    38. Bargaining Power of Buyers
    39. Threat of New Entrants
    40. Threat of Substitutes
    41. Intensity of Rivalry
    42. COVID-19 Impact Analysis
    43. Market Impact Analysis
    44. Regional Impact
    45. Opportunity and Threat Analysis
    46. Cancer Diagnostics Market, BY Test Type (USD Billion)
    47. Biopsy
    48. Imaging
    49. Blood Tests
    50. Molecular Testing
    51. Cancer Diagnostics Market, BY Cancer Type (USD Billion)
    52. Breast Cancer
    53. Lung Cancer
    54. Prostate Cancer
    55. Colorectal Cancer
    56. Cancer Diagnostics Market, BY End User (USD Billion)
    57. Hospitals
    58. Diagnostic Laboratories
    59. Research Institutes
    60. Cancer Diagnostics Market, BY Sample Type (USD Billion)
    61. Tissue Samples
    62. Blood Samples
    63. Urine Samples
    64. Cancer Diagnostics Market, BY Regional (USD Billion)
    65. North America
    66. US
    67. Canada
    68. Europe
    69. Germany
    70. UK
    71. France
    72. Russia
    73. Italy
    74. Spain
    75. Rest of Europe
    76. APAC
    77. China
    78. India
    79. Japan
    80. South Korea
    81. Malaysia
    82. Thailand
    83. Indonesia
    84. Rest of APAC
    85. South America
    86. Brazil
    87. Mexico
    88. Argentina
    89. Rest of South America
    90. MEA
    91. GCC Countries
    92. South Africa
    93. Rest of MEA
    94. Competitive Landscape
    95. Overview
    96. Competitive Analysis
    97. Market share Analysis
    98. Major Growth Strategy in the Cancer Diagnostics Market
    99. Competitive Benchmarking
    100. Leading Players in Terms of Number of Developments in the Cancer Diagnostics Market
    101. Key developments and growth strategies
    102. New Product Launch/Service Deployment
    103. Merger & Acquisitions
    104. Joint Ventures
    105. Major Players Financial Matrix
    106. Sales and Operating Income
    107. Major Players R&D Expenditure. 2023
    108. Company Profiles
    109. Abbott Laboratories
    110. Financial Overview
    111. Products Offered
    112. Key Developments
    113. SWOT Analysis
    114. Key Strategies
    115. Hologic
    116. Financial Overview
    117. Products Offered
    118. Key Developments
    119. SWOT Analysis
    120. Key Strategies
    121. Myriad Genetics
    122. Financial Overview
    123. Products Offered
    124. Key Developments
    125. SWOT Analysis
    126. Key Strategies
    127. Thermo Fisher Scientific
    128. Financial Overview
    129. Products Offered
    130. Key Developments
    131. SWOT Analysis
    132. Key Strategies
    133. BioMérieux
    134. Financial Overview
    135. Products Offered
    136. Key Developments
    137. SWOT Analysis
    138. Key Strategies
    139. Exact Sciences
    140. Financial Overview
    141. Products Offered
    142. Key Developments
    143. SWOT Analysis
    144. Key Strategies
    145. Castle Biosciences
    146. Financial Overview
    147. Products Offered
    148. Key Developments
    149. SWOT Analysis
    150. Key Strategies
    151. Roche
    152. Financial Overview
    153. Products Offered
    154. Key Developments
    155. SWOT Analysis
    156. Key Strategies
    157. Seegene
    158. Financial Overview
    159. Products Offered
    160. Key Developments
    161. SWOT Analysis
    162. Key Strategies
    163. Illumina
    164. Financial Overview
    165. Products Offered
    166. Key Developments
    167. SWOT Analysis
    168. Key Strategies
    169. Agilent Technologies
    170. Financial Overview
    171. Products Offered
    172. Key Developments
    173. SWOT Analysis
    174. Key Strategies
    175. F. HoffmannLa Roche
    176. Financial Overview
    177. Products Offered
    178. Key Developments
    179. SWOT Analysis
    180. Key Strategies
    181. Qiagen
    182. Financial Overview
    183. Products Offered
    184. Key Developments
    185. SWOT Analysis
    186. Key Strategies
    187. Philips Healthcare
    188. Financial Overview
    189. Products Offered
    190. Key Developments
    191. SWOT Analysis
    192. Key Strategies
    193. Siemens Healthineers
    194. Financial Overview
    195. Products Offered
    196. Key Developments
    197. SWOT Analysis
    198. Key Strategies
    199. Appendix
    200. References
    201. Related Reports

    Cancer Diagnostics Market Segmentation

    Cancer Diagnostics Market By Test Type (USD Billion, 2019-2035)

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    Cancer Diagnostics Market By Cancer Type (USD Billion, 2019-2035)

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    Cancer Diagnostics Market By End User (USD Billion, 2019-2035)

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    Cancer Diagnostics Market By Sample Type (USD Billion, 2019-2035)

    Tissue Samples

    Blood Samples

    Urine Samples

    Cancer Diagnostics Market By Regional (USD Billion, 2019-2035)

    North America

    Europe

    South America

    Asia Pacific

    Middle East and Africa

    Cancer Diagnostics Market Regional Outlook (USD Billion, 2019-2035)

    North America Outlook (USD Billion, 2019-2035)

    North America Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    North America Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    North America Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    North America Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    North America Cancer Diagnostics Market by Regional Type

    US

    Canada

    US Outlook (USD Billion, 2019-2035)

    US Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    US Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    US Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    US Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    CANADA Outlook (USD Billion, 2019-2035)

    CANADA Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    CANADA Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    CANADA Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    CANADA Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    Europe Outlook (USD Billion, 2019-2035)

    Europe Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    Europe Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    Europe Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    Europe Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    Europe Cancer Diagnostics Market by Regional Type

    Germany

    UK

    France

    Russia

    Italy

    Spain

    Rest of Europe

    GERMANY Outlook (USD Billion, 2019-2035)

    GERMANY Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    GERMANY Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    GERMANY Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    GERMANY Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    UK Outlook (USD Billion, 2019-2035)

    UK Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    UK Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    UK Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    UK Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    FRANCE Outlook (USD Billion, 2019-2035)

    FRANCE Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    FRANCE Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    FRANCE Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    FRANCE Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    RUSSIA Outlook (USD Billion, 2019-2035)

    RUSSIA Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    RUSSIA Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    RUSSIA Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    RUSSIA Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    ITALY Outlook (USD Billion, 2019-2035)

    ITALY Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    ITALY Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    ITALY Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    ITALY Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    SPAIN Outlook (USD Billion, 2019-2035)

    SPAIN Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    SPAIN Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    SPAIN Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    SPAIN Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    REST OF EUROPE Outlook (USD Billion, 2019-2035)

    REST OF EUROPE Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    REST OF EUROPE Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    REST OF EUROPE Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    REST OF EUROPE Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    APAC Outlook (USD Billion, 2019-2035)

    APAC Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    APAC Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    APAC Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    APAC Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    APAC Cancer Diagnostics Market by Regional Type

    China

    India

    Japan

    South Korea

    Malaysia

    Thailand

    Indonesia

    Rest of APAC

    CHINA Outlook (USD Billion, 2019-2035)

    CHINA Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    CHINA Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    CHINA Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    CHINA Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    INDIA Outlook (USD Billion, 2019-2035)

    INDIA Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    INDIA Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    INDIA Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    INDIA Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    JAPAN Outlook (USD Billion, 2019-2035)

    JAPAN Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    JAPAN Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    JAPAN Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    JAPAN Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    SOUTH KOREA Outlook (USD Billion, 2019-2035)

    SOUTH KOREA Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    SOUTH KOREA Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    SOUTH KOREA Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    SOUTH KOREA Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    MALAYSIA Outlook (USD Billion, 2019-2035)

    MALAYSIA Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    MALAYSIA Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    MALAYSIA Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    MALAYSIA Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    THAILAND Outlook (USD Billion, 2019-2035)

    THAILAND Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    THAILAND Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    THAILAND Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    THAILAND Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    INDONESIA Outlook (USD Billion, 2019-2035)

    INDONESIA Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    INDONESIA Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    INDONESIA Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    INDONESIA Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    REST OF APAC Outlook (USD Billion, 2019-2035)

    REST OF APAC Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    REST OF APAC Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    REST OF APAC Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    REST OF APAC Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    South America Outlook (USD Billion, 2019-2035)

    South America Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    South America Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    South America Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    South America Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    South America Cancer Diagnostics Market by Regional Type

    Brazil

    Mexico

    Argentina

    Rest of South America

    BRAZIL Outlook (USD Billion, 2019-2035)

    BRAZIL Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    BRAZIL Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    BRAZIL Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    BRAZIL Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    MEXICO Outlook (USD Billion, 2019-2035)

    MEXICO Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    MEXICO Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    MEXICO Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    MEXICO Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    ARGENTINA Outlook (USD Billion, 2019-2035)

    ARGENTINA Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    ARGENTINA Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    ARGENTINA Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    ARGENTINA Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    REST OF SOUTH AMERICA Outlook (USD Billion, 2019-2035)

    REST OF SOUTH AMERICA Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    REST OF SOUTH AMERICA Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    REST OF SOUTH AMERICA Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    REST OF SOUTH AMERICA Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    MEA Outlook (USD Billion, 2019-2035)

    MEA Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    MEA Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    MEA Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    MEA Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    MEA Cancer Diagnostics Market by Regional Type

    GCC Countries

    South Africa

    Rest of MEA

    GCC COUNTRIES Outlook (USD Billion, 2019-2035)

    GCC COUNTRIES Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    GCC COUNTRIES Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    GCC COUNTRIES Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    GCC COUNTRIES Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    SOUTH AFRICA Outlook (USD Billion, 2019-2035)

    SOUTH AFRICA Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    SOUTH AFRICA Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    SOUTH AFRICA Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    SOUTH AFRICA Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    REST OF MEA Outlook (USD Billion, 2019-2035)

    REST OF MEA Cancer Diagnostics Market by Test Type

    Biopsy

    Imaging

    Blood Tests

    Molecular Testing

    REST OF MEA Cancer Diagnostics Market by Cancer Type

    Breast Cancer

    Lung Cancer

    Prostate Cancer

    Colorectal Cancer

    REST OF MEA Cancer Diagnostics Market by End User Type

    Hospitals

    Diagnostic Laboratories

    Research Institutes

    REST OF MEA Cancer Diagnostics Market by Sample Type

    Tissue Samples

    Blood Samples

    Urine Samples

    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Related Reports

    Regional Reports
    Country Reports

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials
    Global Magnesium Sulfate Market – Forecast till 2027